| Mr Joshua S Watson, MSW | |
|
2121 7th St, Parkersburg, WV 26101-3803 | |
| (304) 485-1721 | |
| (304) 485-6710 |
| Full Name | Mr Joshua S Watson |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 2121 7th St, Parkersburg, West Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184821639 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Joshua S Watson, MSW 1706 19th St, Parkersburg, WV 26101-3504 Ph: (304) 893-3553 | Mr Joshua S Watson, MSW 2121 7th St, Parkersburg, WV 26101-3803 Ph: (304) 485-1721 |
News Archive
Ferrer, a privately-held Spanish pharmaceutical company, today announces that it has licensed commercialisation rights for Ozenoxacin one per cent cream in Canada to Cipher Pharmaceuticals Inc.
Today, EU policymakers, experts, patient representatives and other stakeholders gathered online to discuss the role of hormones in our everyday life, its interlinkage with prevalent non-communicable diseases and the policy measures required to address the many challenges in this rapidly growing area of human health.
Elite and competitive swimmers log between 60,000 and 80,000 meters weekly-swimming the length of an Olympic-sized pool 1,200 times-which places significant stress on their shoulder joints.
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period.
› Verified 4 days ago
Patricia Vann, PHD, LPC Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 7 Rosemar Cir, Parkersburg, WV 26104 Phone: 304-422-7999 Fax: 681-661-0257 | |
Jama J. Schott, LISW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3194 Core Rd, Parkersburg, WV 26104 Phone: 304-485-5185 Fax: 304-485-0051 | |
Rachel A Scheiding, MSW, LICSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 2121 7th Street, Parkersburg, WV 26101 Phone: 304-485-1721 Fax: 304-424-9424 | |
Charmaine Y Dotson, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2801 Dudley Ave, Suite B, Parkersburg, WV 26101 Phone: 304-428-1114 Fax: 304-428-1135 | |
Mr. David M Schaffer, CSW, MSW, LICSW Clinical Social Worker Medicare: May Accept Medicare Assignments Practice Location: 3705 Emerson Ave, Parkersburg, WV 26104 Phone: 304-865-0272 Fax: 304-865-0265 | |
Marcia A Lang, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2121 7th St, Parkersburg, WV 26101 Phone: 304-485-1721 Fax: 304-485-9203 |